UCLA Division of Rheumatology conducts cutting-edge biomedical and health-related research studies that include both interventional and observational studies. Our clinical studies are sponsored/funded by National Institute of Health (NIH), pharmaceutical companies, and/or non-profit medical institutions/organizations.
Treatment/Interventional studies are those in which the research subjects are assigned to a treatment or intervention and their outcomes are measured.
Observational studies are those in which individuals are observed and their outcomes are measured by the study investigators.
Rheumatoid Arthritis
Cholesterol
Gout
Lupus
Scleroderma
Vasculitis
If you would like to get more information on any studies please call us at (310) 825-0096 or email rheumresearch@mednet.ucla.edu.
If you are interested in finding out more information of a particular study, please contact the study personnel.
Study Type | Title of Study | |
| Rheumatoid Arthritis | ||
| Treatment/ Interventional | *Multiple studies | Principal Investigators |
| Treatment/Interventional | Dietary Intervention on Rheumatoid Arthritis Assessed by Ultrasound in over weight patients Status: Recruiting | Principal Investigator Veena K. Ranganath, MD, MS For more information, please contact (310) 825-9956 |
| Treatment/Interventional | Musculoskeletal Ultrasound Predicting Therapeutic Response in Tofacitinib in Rheumatoid Arthritis Patients Status: Recruiting | Principal Investigator Veena K. Ranganath, MD, MS For more information, contact (310) 825-9956 |
| Observational | HDL (Carotid Study): Evaluation of HDL function in patients with and without Rheumatic Disease Status: Open for Enrollment | Principal Investigator Christina Charles, MD For more information, contact Jeraldine Guzman (310) 825-4744 |
| Treatment | AMGEN 20130207: A Multicenter Double-blind, Randomized Controlled study of Etanercept and Methotrexate in cobination or as Monotherapy in subjects with Psoriatic Arthritis Status: Open for Enrollment | Principal Investigator Suzanne Kafaja, MD For more information, contact Jeraldine Guzman (310) 825-4744 |
| Cholesterol | ||
| Observational | HDL Function in Patients With and Without Rheumatic Disease (Investigatory) | Principal Investigators Christina Charles-Schoeman, MD For more information, contact Jeraldine Guzman (310) 825-4744 |
| Gout | ||
| Observational | Gout Cholesterol Study: A study to evaluate the association between gout and cholesterol. Patients undergo blood draw and Dual Energy CAT Scan (to measure amount of gouty deposits). | Principal Investigators John FitzGerald, MD For more information, contact (310) 794-5100 |
| Lupus | ||
| Treatment | Efficacy of Abatacept (Orencia®) in inflammatory Polyarthritis of Systemic Lupus Erythematosus (SLE) Status: Recruiting | Principal Investigator Bevra Hahn, MD For more information contact |
| Treatment | Rituximab plus Cyclophosphamide followed by Belimumab for the treatment of Lupus Nephritis (CALIBRATE) Status: Recruiting | Principal Investigators Maureen McMahon, MD For more information contact |
| Treatment | Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (STOP RA) Status: Recruiting | Principal Investigators For more information contact |
| Treatment | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with active Proliferative Lupus Nephritis Status: Recruiting | Principal Investigator Jennifer Grossman, MD For more information, contact Mia Vasquez-Gutierrez (310) 825-6461 |
| Treatment | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating Efficacy and Safety of Anifrolumab in Adult subjects with Active Systemic Lupus Erythematosus (SLE) Status: Recruiting | Principal Investigator Jennifer Grossman, MD For more information, contact Mia Vasquez-Gutierrez (310) 825-6461 |
| Observational | Biomarkers in Lupus Status: Recruiting | Principal Investigator Ram Raj Singh, MD For more information contact Ram Raj Singh, MD |
| Observational | The Role of Gender Factors in Lupus and Autoimmunity Status: Recruiting | Principal Investigator Ram Raj Singh, MD For more information contact |
| Observational | Autoimmunity Characteristics in Patients with Systemic Lupus Erythematosus versus Health Controals Status: Recruiting | Principal Investigator Jennifer King, MD For more information contact |
| Observational | Observational, Mechanisms of Inflammation and Immune Response in Skin Dermatoses. Status: Recruiting | Principal Investigator Jennifer King, MD For more information contact |
| Treatment/ Interventional | *Multiple studies Status: Recruiting | Principal Investigators Jennifer Grossman, MD; Maureen McMahon, MD For more information, contact Mia Vasquez-Gutierrez (310) 825-6461 |
| Scleroderma | ||
| Treatment/ Interventional | *Multiple studies | Principal Investigator TBD |
| Treatment | ROCHE WA29767: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab versus Placebo in Patients with Systemic Sclerosis Status: Open for Enrollment | Principal Investigators Suzanne Kafaja, MD For more information contact
|
| Observational | SPIN: The Scleroderma Patient-Centered Intervention Network (SPIN) Cohort Status: Open for Enrollment
| Principal Investigator For more information, contact Nashla Barroso (310) 825-9682 |
| Observational | Blood and Skin Biopsy Donation: A research study to define the differences in Immune Responses in skin from patients with an autoimmune or inflammatory condition Status: Open for Enrollment | Principal Investigator Suzanne Kafaja, MD For more information, contact |
| Treatment | Bayer 16277: A Randomized, Double-Blind, Placebo-Controlled Phase II study to investigate the Efficacy and Safety of Riociguat in patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc) Status: Open for Enrollment | Principal Investigators For more information, contact Nashla Barroso (310) 825-9682 |
| Treatment | ASSETT IM101-344: A phase II study to evaluate subcutaneous Abatacept vs. Placebo in diffuse cutaneous systemic sclerosis--a double-blind, placebo-controlled, randomized controlled trial Status: Open for Enrollment | Principal Investigator Suzanne Kafaja, MD For more information, contact Jeraldine Guzman (310) 825-4744 |
| Treatment | Scleroderma Treatment with Autologus Transplant (STAT) Study: A phase II multi-center study of high-dose Cyclophosphamide and Antithymocyte Globulin followed by Autologus Hematopoietic Cell Transplant with post transplant maintenance for the treatment of Systemic Sclerosis Status: Open for Enrollment | Principal Investigator Suzanne Kafaja, MD For more information, contact Jeraldine Guzman (310) 825-4744 |
| Other | PHAROS: Outcome Studies in Systemic Sclerosis: A Prospective Database of Echocardiograms and PFTs on Patients with Limited Scleroderma (Standard of Care) Status: Recruiting | Principal Investigators For more information, contact Nashla Barroso (310) 825-9682 |
| Observational | Quality od Life: Quality of Life of people with scleroderma: Health values and minimally important differences of people with scleroderma Status: Open for Enrollment | Principal Investigator Suzanne Kafaja, MD For more information, contact Nashla Barroso (310) 825-9682 |
| Vasculitis | ||
| Treatment | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis" This is a phase 3 clinical trial evaluating Sirukumab (a monoclonal antibody against interleukin 6) in patients with giant cell arteritis. Status: Recruiting | Principal Investigator Tanaz Kermani, MD For more information contact |
